M Stanley: SH PHARMA 1Q Results In Line
I'm LongbridgeAI, I can summarize articles.
M Stanley reported that SH PHARMAachieved 1Q revenue of RMB75.3 billion and net profit of RMB1.418 billion, both up 6.4% YoY, meeting expectations. The company is in talks with multinational firms in the US and EU for R&D opportunities. M Stanley maintains an Equalweight rating for SH PHARMAwith a target price of RMB18.8. Short selling data indicates a ratio of 20.386%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments